Survey finds hazardous chemicals in garments, surface water of five rivers near textile hubs
New Delhi: A new report by an NGO has revealed the presence of hazardous hormone-disrupting chemicals in garments sold across India, including innerwear, as well as on surface water of five rivers near textile hubs.
The study by Toxics Link published in the report titled "Toxic Threads: Assessing Nonylphenol in Indian Textiles and the Environment" found
nonylphenol ethoxylates
(NPEs) -- a group of endocrine-disrupting chemicals -- in 15 out of 40 textile products examined.
These garments were sourced from popular retail shops and online platforms in 10 major textile hubs across the country, according to the report released on Monday.
Ten of the NPE-contaminated items were innerwear, with one female hosiery product recording the highest concentration of 957 milligram/kilogramme.
Sixty per cent of baby and children's garments tested also contained NPEs, according to the report.
NPEs and their breakdown product, nonylphenol (NP), are known to mimic estrogen, disrupting the hormonal system and increasing the risk of developmental disorders and cancers, Toxics Link said in the report.
Despite their documented health risks, these chemicals continue to be widely used in India in textiles and various industrial sectors, including leather, detergents, food packaging, and cosmetics, it said.
"These chemicals are known endocrine disruptors, and their detection in clothing and riverwater is a serious public health issue," said Toxics Link associated director Satish Sinha.
"India needs to urgently regulate the use of nonylphenol not just in cosmetics but also in textiles and industrial effluent," he added.
The study also tested environmental samples and detected NPEs in the surface water of five rivers -- Cooum and Adyar in Chennai, Buddha Nullah in Ludhiana, Bandi river in Pali, and Sabarmati in Ahmedabad.
The Cooum recorded the highest NPE concentration at 70 micrograms/litre while the Buddha Nullah had the highest NP contamination in sediment samples at 460 micrograms/kilogramme and mixed isomers at 1,190 micrograms/kilogramme.
The presence of these chemicals was confined to downstream locations near textile hubs, pointing to industrial discharges as the likely source.
NP, which is persistent and bio-accumulative in nature, poses a long-term risk to aquatic ecosystems and human health.
India restricts NP only in cosmetics while several other countries have set broader regulations due to its toxicity, according to the report.
Toxics Link has called for a national action plan to regulate NP use in textiles, including stricter monitoring of industrial effluent and promotion of safer, biodegradable alternatives.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
India.com
3 hours ago
- India.com
Low Effort, High Flavor: Paneer Salad Bowls For Every Day
Anaika Sohal Jun 05, 2025 This healthy bowl is made with grilled tandoori paneer cubes with cucumber, onions, cherry tomatoes, and mint-yogurt dressing. An Indian twist to the bowl by adding sauteed paneer in Indian spices over shredded lettuce, corn, bell peppers, and lemon juice. A quick and healthy breakfast recipe made from crumbled paneer tossed with cooked quinoa, parsley, olives, and a light olive oil-lime vinaigrette. A different unique variety of paneer bowl tempered with mustard seeds and curry leaves, served with grated carrot, coconut, and soaked moong dal. Tasty and healthy version of paneer bowl with soft paneer cubes with avocado slices, microgreens, roasted sunflower seeds, and tahini dressing. A tropical bowl made with cubed paneer, cherry tomatoes, cucumber, lettuce, and a drizzle of lemon-garlic hummus. For this recipe add baked or air-fried chilli paneer with sautéed broccoli, red cabbage, and a sesame-soy glaze. Read Next Story
Time of India
3 hours ago
- Time of India
NTET 2025 registration begins at exams.nta.ac.in: Apply online by this date, check direct link here
The National Testing Agency ( NTA ) has commenced the registration process for the National Teachers Eligibility Test (NTET) 2025, aimed at postgraduates in Indian systems of medicine and homoeopathy aspiring to become educators. The examination is scheduled for July 17, 2025. Aspirants seeking to appear for the exam must possess postgraduate qualifications in disciplines such as Ayurveda, Siddha, Unani, or Homoeopathy. Acceptable combinations include degrees like BAMS with MD/MS in Ayurveda, BHMS with MD in Homoeopathy, and BUMS with MD in Unani, among others. Additionally, qualifications like MSc in Anatomy, Physiology, Biochemistry, and Master of Public Health are recognized. NTET 2025 Important Dates Candidates appearing for the NTET 2025 exam are advised to check all the important dates mentioned below: Application Period: June 4 to June 23, 2025 (until 11:50 PM) Fee Payment Deadline: June 24, 2025 (until 11:50 PM) Correction Window: June 25 to June 27, 2025 Examination Date: July 17, 2025 NTET 2025 Application Fees To register for the NTET 2025 examination, applicants must fill the registration form along with the application fee. Check category wise application fee amount below: General Category: Rs. 4,000 General-EWS/OBC-NCL: Rs. 3,500 SC/ST/PwD/Third Gender: Rs. 3,000 Fees can be paid online through the official portal. How to apply for NTET 2025? Here is how candidates can register online for NTET 2025 examination: Visit the official website: Register and fill out the application form. Upload necessary documents, including a recent photograph, signature, educational certificates, and valid ID proof. Pay the application fee online. Submit the form and retain a copy for future reference. Direct link to apply for NTET 2025 For more details, candidates should refer to the official information bulletin available on the NTA website. Ready to navigate global policies? Secure your overseas future. Get expert guidance now!
